Provincial and Municipal Drug “Fast-Track Review” Initiative Deepens in the Jinggangshan Economic Development Zone

On the afternoon of March 10, the Provincial–Municipal Drug Review Service Express (Jinggangshan Economic Development Zone Station) and Policy Briefing Symposium was successfully held at Jiangxi Institute of Biological Products Co., Ltd. As a co-organizer of the event, the company provided comprehensive coordination and support throughout the proceedings and proactively opened its core production facilities, demonstrating strong commitment and responsibility in building an efficient communication bridge between government and enterprises. This initiative effectively brought review services closer to the front lines and delivered targeted support to foster the development of the biopharmaceutical industry.

Fully collaborate to provide support and safeguard, solidifying the platform for government-enterprise exchange.

This symposium focused on the core needs of biopharmaceutical companies, including regulatory review and submission processes and the effective implementation of relevant policies, with the overarching goal of leveraging government–enterprise collaboration to deliver targeted services and enhance the quality and efficiency of the industry. Jiangxi Bio proactively coordinated efforts across the board, from meticulous venue setup and guest reception and guidance to detailed event scheduling and tour route planning, ensuring the smooth execution of policy briefings, interactive Q&A sessions, and other key components. In doing so, it created a professional and efficient face-to-face communication platform for experts from provincial and municipal drug regulatory authorities and representatives from more than 30 pharmaceutical companies across various industrial parks in Ji’an City. As a leading local biopharmaceutical enterprise, the company has taken proactive responsibility by helping shift government services toward a “proactive outreach” model—bringing tangible policy packages directly to businesses—and thereby laying a solid foundation for the joint establishment of a provincial–local drug review service window.

Open access to the production floor, showcasing core capabilities in real-world settings.

Following the symposium, all attendees embarked on a guided tour of the company’s production facilities, gaining firsthand insight into key operational areas such as pharmaceutical R&D, large-scale manufacturing, and end-to-end quality control. From state-of-the-art cleanrooms to highly specialized quality-testing laboratories, the guests closely observed the biopharmaceutical industry’s stringent manufacturing standards, robust quality-control systems, and cutting-edge R&D capabilities. This immersive visit broke away from the conventional one-way presentation format of typical conferences, creating a scenario-based platform for industry dialogue that aligns policy requirements with real-world business practices. It provided a vivid example of how regional pharmaceutical companies can collaborate, learn from one another, and draw mutual inspiration, thereby fostering synergistic development across the sector.

Breaking the Impasse in Precision Services to Jointly Promote High-Quality Industrial Development

At the event, experts from the Provincial Drug Certification and Review Center provided an in-depth interpretation of the latest review policies, application procedures, and common issues related to “two products and one medical device.” They addressed specific pain points and challenges raised by enterprises—such as technical reviews, document compliance, and on-site inspections—providing clear answers and solutions to effectively remove barriers to development. Leveraging its role as a co-organizer, Jiangxi Bio facilitated close collaboration between government and industry, ensuring that high-quality review services reach the end-users in the sector, thereby helping policy benefits to be delivered precisely and efficiently. This initiative also accumulated valuable experience for establishing routine, end-to-end support services for enterprises going forward.

This “Direct Channel for Review and Approval Services” initiative focuses on the development of the biopharmaceutical industry, leveraging service to drive improvement and pragmatic action to achieve mutual benefit. By combining policy briefings in conference rooms with on-site, real-world exchanges at production facilities, the initiative has created a two-way empowerment effect. It not only underscores Jiangxi Bio’s corporate responsibility and its status as an industry benchmark, but also further streamlines channels for government–enterprise collaboration. Moving forward, the company will continue to capitalize on its strengths, actively support the optimization and upgrading of the regional biopharmaceutical sector, and work hand-in-hand with government and business stakeholders to build a new high ground for industrial development.